Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARE: Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart in Rectal Cancer
NCT07810114Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of suvemcitug and PBI-1308 in rectal cancer, sponsored by Fudan University. Primary endpoint: Pathologic Complete Response Rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
suvemcitugPBI-1308
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07810114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07810114.